Vaccine Expert Joins Geneius’s Coronavirus Program
Geneius Biotechnology, Inc., a developmental stage biotechnology company pioneering natural T cell therapeutics for medical conditions associated with viruses and cancer and prevention of virus infections, announces that Wolfgang Klietmann, M.D., FCAP, is joining the company to advise on its coronavirus program. Dr. Klietmann is a Clinical Pathologist and Medical Microbiologist, served on the Faculty of Harvard Medical School, and held a staff member position at the Department of Pathology at the Massachusetts General Hospital. He heads an international healthcare consulting company.
Prior to his immigration to the United States in 1992, Klietmann founded and was President and Physician-in-Chief of a major Institute of Laboratory Medicine in Germany, which he built into a peerless institution in its scientific standing and innovative diagnostic reputation among private laboratories in Germany. For 12 years he headed a scientific collaboration as Primary Investigator with the Insitut Mérieux in Lyon (France) on Rabies Vaccines involving the WHO. The Insitute was bought out by the Pharmaceutical Industry.
Klietmann has received his executive business education at Harvard Business School. He received his medical education at the University of Freiburg (Germany). the University of Paris (France), and graduated with a Diploma from the Sorbonne. He performed research work as an Associate Scientist at the Wistar Institute at the University of Pennsylvania. For five years, Klietmann headed a research group at the Max-Planck-Institute for Virus Research in Tübingen (Germany), and served on the Medical Faculty of the University of Tübingen until receiving his academic appointment at Harvard Medical School.
A prolific author and guest lecturer with over 200 publications and presentations delivered to audiences across the globe, the cornerstone of Klietmann’s career has centered on infectious diseases and vaccines, bringing together individuals and organizations to share information, technology, and resources. His work in Biodefense includes a collaboration with MIT in a project for the Department of Defense. He served as President and for 12 years on the Board of Directors of the Harvard Business School Health Industry Alumni Association, and organized as chairman several major conferences held on the campus of Harvard University and in Washington, DC. His memberships in several scientific societies include a Fellow of the College of American Pathologists. He serves on the Board of the Swiss-American Chamber of Commerce in Boston.